UPDATE August 25th, 2016 — Seattle Genetics, Inc. (NASDAQ:SGEN) surged +1.55% and closed the trade at $ 47.79. Clay Siegall, CEO, played vital role in increasing the value of Seattle Genetics
In 1998 Clay Siegall co-founded Seattle Genetics as a culmination of his desire to find a cure for cancer. He helped in all aspects of his company’s development including private and public fundraising and brought the company public in 2001. Dr. Siegall is a man driven by a desire to discover a cure for a disease that takes hundreds of thousands of lives each year, destroying families and depleting the funds of insurance companies and family savings accounts.
He began by studying Zoology at the University of Maryland where he obtained a B.S. and continued by earning his Ph.D. in Genetics from George Washington University. Before founding Seattle Genetics, he worked with the Bristol-Meyers Squibb Pharmaceutical Research Institute and the National Cancer Institute. He serves on several research-related boards of directors.
Seattle Genetics has been developing a portfolio of products aimed at cancer and autoimmune diseases. The company has been advancing antibody technologies in a special class of antibody drugs that selectively attack cancer cells while leaving healthy cells alive and well. All too often the invasive and destructive effects of cancer treatments leave the human body with less cancer but weakening the body as well. Cancer is the scourge of society and companies like Seattle Generics and people like Clay Siegall are desperately needed in finding a cure.
The Seattle area has become a focal point for medical drug research and scientists are creating a family and work friendly environment in this part of Washington. The climate and the mountainous natural resources nearby suit the scientists and their families as they work and relax in this area. The world has Wall Street for finances, and Silicon Valley for computer, cell phone, and electronic research and now Seattle as a center for cancer research.